Drug Trial Radar · NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
453
Planned (sponsor's estimate)
Start
Apr 17, 2018
Primary completion
Apr 20, 2028
Study completion Jul 7, 2029
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding. The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Small Cell Lung Cancer (SCLC)
- Follicular Lymphoma (FL)
Interventions
Mevrometostat (PF-06821497)Drug
Oral continuous
EnzalutamideDrug
Oral continuous
ItraconazoleDrug
Oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)Time frame: Baseline up to 90 days
- Overall safety profile including adverse eventsTime frame: Baseline up to approximately 2 years
- Preliminary efficacy determination as evaluated by disease specific response criteriaTime frame: Through study completion, approximately 2 years past last patient first visit.
- Overall safety profile including laboratory abnormalitiesTime frame: Baseline up to approximately 2 years
- Overall safety profile including vital signsTime frame: Baseline up to approximately 2 years
- Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survivalTime frame: Baseline until disease progression or death or through study completion (approx 2 years)
Locations
84 sites in 8 countries. Site status is shown where the registry gives one.
Banner-University Medical Center Tucson
Tucson, Arizona · Active not recruiting
The University of Arizona Cancer Center-North Campus
Tucson, Arizona · Active not recruiting
The University of Arizona Cancer Center
Tucson, Arizona · Active not recruiting
Arizona Urology Specialists, PLLC
Tucson, Arizona · Terminated
Pacific Cancer Medical Center INC
Anaheim, California · Active not recruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California · Active not recruiting
City of Hope Investigational Drug Services (IDS)
Duarte, California · Active not recruiting
Norwalk Hospital
Norwalk, Connecticut · Active not recruiting
The University of Kansas Cancer Center, Investigational Drug Services
Fairway, Kansas · Active not recruiting
The University of Kansas Clinical Research Center
Fairway, Kansas · Active not recruiting
The University of Kansas Hospital
Kansas City, Kansas · Active not recruiting
The University of Kansas Medical Center Medical Office Building
Kansas City, Kansas · Active not recruiting
The University of Kansas Cancer Center - Indian Creek Campus
Overland Park, Kansas · Active not recruiting
The University of Kansas Cancer Center
Westwood, Kansas · Active not recruiting
Norton Cancer Institute - Downtown
Louisville, Kentucky · Active not recruiting
Norton Cancer Institute, Norton Healthcare Pavilion
Louisville, Kentucky · Active not recruiting
Norton Hospital
Louisville, Kentucky · Active not recruiting
Maryland Oncology Hematology, P.A.
Rockville, Maryland · Terminated
Brigham and Women's Hospital
Boston, Massachusetts · Active not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
Dana Farber Cancer Institute- Chestnut Hill
Newton, Massachusetts · Active not recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Active not recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Active not recruiting
OU Health University of Oklahoma Medical Center
Oklahoma City, Oklahoma · Recruiting
Stephenson Cancer Center (chemo location)
Oklahoma City, Oklahoma · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Parkway Surgery Center
Myrtle Beach, South Carolina · Recruiting
Sarah Cannon Research Institute - Pharmacy
Nashville, Tennessee · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - Austin Midtown
Austin, Texas · Terminated
University of Texas Southwestern Medical Center - Simmons Cancer Center
Dallas, Texas · Active not recruiting
UT Southwestern Medical Center
Dallas, Texas · Active not recruiting
UT Southwestern University Hospital - William P. Clements, Jr
Dallas, Texas · Active not recruiting
UT Southwestern University Hospital - Zale Lipshy
Dallas, Texas · Active not recruiting
NEXT Dallas
Irving, Texas · Recruiting
US Oncology Investigational Product Center (IPC)
Irving, Texas · Terminated
US Oncology Investigational Products Center
Irving, Texas · Terminated
NEXT Oncology
San Antonio, Texas · Recruiting
Virginia Cancer Specialists, PC
Fairfax, Virginia · Active not recruiting
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.